AVANIR to Change Listing to the NASDAQ National Market System; Trading will Commence on April 11, Under the Ticker Symbol AVNR
04 4월 2006 - 5:15AM
Business Wire
AVANIR Pharmaceuticals (AMEX:AVN.R) announced today that the
NASDAQ(R) has approved the Company's application for listing on the
NASDAQ National Market System. Consistent with NASDAQ guidance,
trading is expected to begin on Tuesday, April 11, under the new
ticker symbol "AVNR." Until that time, AVANIR's stock will continue
to trade on the American Stock Exchange under the symbol "AVN.R."
About AVANIR AVANIR Pharmaceuticals is focused on developing and
commercializing novel therapeutic products for the treatment of
chronic diseases. AVANIR's product candidates address therapeutic
markets that include central nervous system and cardiovascular
disorders, inflammation, and infectious diseases. AVANIR previously
announced positive results in the second of two required Phase III
clinical trials of Neurodex(TM), an investigational new drug for
the treatment of involuntary emotional expression disorder (IEED).
Additionally, AVANIR has initiated a Phase III clinical trial for
Neurodex as a potential treatment in patients with diabetic
neuropathic pain, a second indication for Neurodex. AVANIR has
active collaborations with two international pharmaceutical
companies: Novartis International Pharmaceutical Ltd., for the
treatment of inflammatory disease and AstraZeneca, for the
treatment of cardiovascular disease. The Company's first
commercialized product, "abreva(R)", is marketed in North America
by GlaxoSmithKline Consumer Healthcare and is the leading
over-the-counter product for the treatment of cold sores. Further
information about AVANIR can be found at www.avanir.com. FORWARD
LOOKING STATEMENT Statements in this press release that are not
historical facts, including statements that are preceded by,
followed by, or that include such words as "estimate,"
"anticipate," "believe," "plan," or "expect," or similar
statements, are forward-looking statements that are subject to
certain risks and uncertainties that could cause actual results to
differ materially from the future results expressed or implied by
such statements. There can be no assurance that Neurodex will
receive regulatory approval; or that if such regulatory approval is
received, AVANIR will be able to market Neurodex successfully.
Final review decisions made by the FDA and other regulatory
agencies concerning clinical trial results are often unpredictable
and outside the influence and/or control of the company. Risks and
uncertainties also include the risks set forth in AVANIR's most
recent Annual Report on Form 10-K and subsequent Quarterly Reports
on Form 10-Q and from time-to-time in other publicly available
information regarding the Company. Copies of this information are
available from AVANIR upon request. AVANIR disclaims any intent or
obligation to update these forward-looking statements.
Avanir (AMEX:AVN.R)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Avanir (AMEX:AVN.R)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Avanir Pharmaceuticl (아메리카 증권거래소)의 실시간 뉴스: 최근 기사 0
More AVANIR Pharmaceuticals News Articles